Lifesci Capital Initiates Coverage on Protara Therapeutics (NASDAQ:TARA)
Investment analysts at Lifesci Capital started coverage on shares of Protara Therapeutics (NASDAQ:TARA – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat reports. The firm set an “outperform” rating and a $22.00 price target on the stock. Lifesci Capital’s price objective points to a potential upside of 440.54% […]
Investment analysts at Lifesci Capital started coverage on shares of Protara Therapeutics (NASDAQ:TARA – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat reports. The firm set an “outperform” rating and a $22.00 price target on the stock. Lifesci Capital’s price objective points to a potential upside of 440.54% […]
